BACKGROUND: Acute rejection remains a major source of morbidity after lung transplantation. Given the importance of this diagnosis, an international grading system was developed to standardize the diagnosis of acute lung-allograft rejection. The reliability of this grading system has not been adequately assessed by previous studies. METHODS: We examined the level of agreement in grading transbronchial biopsy specimens obtained from a large multicenter study (AIRSAC [Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen vs Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation] trial). Biopsy specimens were initially graded for acute rejection and lymphocytic bronchiolitis by the site pathologist and subsequently graded by a central pathologist. Reliability of interobserver grading was evaluated using Cohen κ coefficients. RESULTS: A total of 481 transbronchial biopsy specimens were graded by both the site and central pathologists. The overall concordance rates were 74% and 89% for grade A and grade B biopsy specimens, respectively. When samples from biopsies performed at different time points after transplantation were assessed, there was a higher level of agreement early (≤ 6 weeks) after transplant compared with later time points for acute rejection. However, there was still only moderate agreement for both grade A (κ score 0.479; 95% CI, 0.29-0.67) and grade B (κ score 0.465; 95% CI, 0.08-0.85) rejection. CONCLUSIONS: These results expand upon previous reports of interobserver variability in grading transbronchial biopsy specimens after lung transplantation. Given the variability in grading these specimens, we advocate further education of the histopathologic findings in lung transplant biopsy specimens, as well as revisiting the current criteria for grading transbronchial biopsy specimens to improve concordance among lung transplant pathologists. TRIAL REGISTRY: ClinicalTrials.gov; No. NCT00321906; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: Acute rejection remains a major source of morbidity after lung transplantation. Given the importance of this diagnosis, an international grading system was developed to standardize the diagnosis of acute lung-allograft rejection. The reliability of this grading system has not been adequately assessed by previous studies. METHODS: We examined the level of agreement in grading transbronchial biopsy specimens obtained from a large multicenter study (AIRSAC [Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen vs Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation] trial). Biopsy specimens were initially graded for acute rejection and lymphocytic bronchiolitis by the site pathologist and subsequently graded by a central pathologist. Reliability of interobserver grading was evaluated using Cohen κ coefficients. RESULTS: A total of 481 transbronchial biopsy specimens were graded by both the site and central pathologists. The overall concordance rates were 74% and 89% for grade A and grade B biopsy specimens, respectively. When samples from biopsies performed at different time points after transplantation were assessed, there was a higher level of agreement early (≤ 6 weeks) after transplant compared with later time points for acute rejection. However, there was still only moderate agreement for both grade A (κ score 0.479; 95% CI, 0.29-0.67) and grade B (κ score 0.465; 95% CI, 0.08-0.85) rejection. CONCLUSIONS: These results expand upon previous reports of interobserver variability in grading transbronchial biopsy specimens after lung transplantation. Given the variability in grading these specimens, we advocate further education of the histopathologic findings in lung transplant biopsy specimens, as well as revisiting the current criteria for grading transbronchial biopsy specimens to improve concordance among lung transplant pathologists. TRIAL REGISTRY: ClinicalTrials.gov; No. NCT00321906; URL: www.clinicaltrials.gov.
Authors: Jun Zou; Brian Duffy; Michael Slade; Andrew Lee Young; Nancy Steward; Ramsey Hachem; T Mohanakumar Journal: Hum Immunol Date: 2017-03-04 Impact factor: 2.850
Authors: Jinbang Guo; Howard J Huang; Xingan Wang; Wei Wang; Henry Ellison; Robert P Thomen; Andrew E Gelman; Jason C Woods Journal: Magn Reson Med Date: 2014-06-20 Impact factor: 4.668
Authors: J R Greenland; N P Jewell; M Gottschall; N N Trivedi; J Kukreja; S R Hays; J P Singer; J A Golden; G H Caughey Journal: Am J Transplant Date: 2014-02-11 Impact factor: 8.086
Authors: Sean Agbor-Enoh; Joshua L Chan; Avneesh Singh; Ilker Tunc; Sasha Gorham; Jun Zhu; Mehdi Pirooznia; Philip C Corcoran; Marvin L Thomas; Billeta G T Lewis; Moon Kyoo Jang; David L Ayares; Keith A Horvath; Muhammad M Mohiuddin; Hannah Valantine Journal: J Heart Lung Transplant Date: 2018-04-26 Impact factor: 10.247
Authors: John R Greenland; Charissa M Wong; Rahul Ahuja; Angelia S Wang; Chiyo Uchida; Jeffrey A Golden; Steven R Hays; Lorriana E Leard; Raja Rajalingam; Jonathan P Singer; Jasleen Kukreja; Paul J Wolters; George H Caughey; Qizhi Tang Journal: Transplantation Date: 2016-10 Impact factor: 4.939
Authors: M Y Shino; S S Weigt; N Li; A Derhovanessian; D M Sayah; R Saggar; R H Huynh; A L Gregson; A Ardehali; D J Ross; J P Lynch; R M Elashoff; J A Belperio Journal: Am J Transplant Date: 2017-08-02 Impact factor: 9.369
Authors: Moon Kyoo Jang; Ilker Tunc; Gerald J Berry; Charles Marboe; Hyesik Kong; Michael B Keller; Pali D Shah; Irina Timofte; Anne W Brown; Ileana L Ponor; Cedric Mutebi; Mary C Philogene; Kai Yu; Aldo Iacono; Jonathan B Orens; Steven D Nathan; Sean Agbor-Enoh Journal: J Heart Lung Transplant Date: 2021-04-24 Impact factor: 13.569
Authors: Michael Y Shino; Ning Li; Jamie L Todd; Megan L Neely; Jerry Kirchner; Heather Kopetskie; Michelle L Sever; Courtney W Frankel; Laurie D Snyder; Elizabeth N Pavlisko; Tereza Martinu; Lianne G Singer; Wayne Tsuang; Marie Budev; Pali D Shah; John M Reynolds; Nikki Williams; Mark A Robien; Scott M Palmer; Stephen Sam Weigt; John A Belperio Journal: Am J Transplant Date: 2021-06-16 Impact factor: 9.369